All In Biotech

NDA 022278 · Dorc

Membraneblue

Trypan Blue · Ophthalmic

Priority reviewOrphanDiscontinued

Last checked: Nov 20, 2026Latest source record: Nov 17, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2009

Feb 20, 2009

Approved uses

1

Original approval plus efficacy supplements

Registered trials

4

0 Phase 3, 1 recruiting

FAERS reports

34

32 serious, 1 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 24, 2025.

MembraneBlue 0.15% - Indications & Usage Section MembraneBlue™ 0.15% is indicated for use as an aid in ophthalmic surgery by staining the epiretinal membranes during ophthalmic surgical vitrectomy procedures, facilitating removal of the tissue in adults and pediatric patients. These highlights do not include all the information needed to use MEMBRANEBLUE™ safely and effectively. See full prescribing information for MEMBRANEBLUE. MEMBRANEBLUE (trypan blue ophthalmic solution) 0.15%, for intraocular ophthalmic use Initial U.S. Approval: 2004 MembraneBlue is a diagnostic dye indicated for use as an aid in ophthalmic posterior surgery by staining the epiretinal membranes during ophthalmic surgical vitrectomy procedures, facilitating removal of epiretinal tissue in adults and pediatric patients

Mechanism: MembraneBlue 0.15% - Mechanism of action section. MembraneBlue 0.15% selectively stains membranes in the human eye during posterior surgery, such as epiretinal membranes (ERM) and Internal Limiting Membranes (ILM).

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Feb 20, 2009 Original approval · Type 5 - New Formulation or New Manufacturer · priority review LabelLetterReview
1 products under this application
  • MEMBRANEBLUE · TRYPAN BLUE 0.15% · SOLUTION, OPHTHALMIC · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Trypan Blue" as an intervention, any sponsor and status, largest first.

All 4 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • blindness22
  • toxic anterior segment syndrome21
  • corneal oedema6
  • product quality issue6
  • cerebral infarction3
  • pigmentation disorder3
  • thyroid disorder3
  • condition aggravated2
  • off label use2
  • vision blurred2
  • corneal degeneration1
  • drug interaction1

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
201421
20166
20191
20215
20221

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 87 on PubMed

Sponsor: Dorc

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.